Nuvation Bio INC 8-K filings

Nuvation Bio announced robust second quarter 2026 financial results, showcasing significant revenue growth for IBTROZI and positive advancements in its safusidenib clinical program.

Nuvation Bio Inc. announced the full exercise of the over-allotment option for its 0.75% Convertible Senior Notes due 2032, raising a total of $287.5 million.

Nuvation Bio Inc. has priced an offering of $250.0 million in aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $37.5 million.

Nuvation Bio Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Nuvation Bio announced first quarter 2026 financial results, with IBTROZI net product revenues of $18.5 million and a significant increase in collaboration and license revenue to $64.7 million, alongside strategic updates including the acquisition of Japan rights for safusidenib.

Nuvation Bio announced robust fourth-quarter and full-year 2025 financial results, highlighting strong IBTROZI adoption and pipeline advancements.

Nuvation Bio announces a significant licensing deal with Eisai for its cancer drug IBTROZI, alongside strong preliminary Q4 and full-year 2025 sales results and a robust cash position.

Nuvation Bio discontinues NUV-1511 development due to inconsistent efficacy, reallocating significant R&D funds to its approved IBTROZI and pivotal safusidenib programs.

Nuvation Bio reports positive Phase 2 safusidenib results for IDH1-mutant gliomas and strong initial commercial uptake for IBTROZI in ROS1+ NSCLC.

Nuvation Bio announced its third-quarter 2025 financial results, highlighting strong initial IBTROZI sales and unprecedented durability data for its lead oncology drug.

Nuvation Bio Inc. announced its second quarter 2025 financial results, highlighted by the recent U.S. FDA approval of IBTROZI for advanced ROS1-positive NSCLC and its rapid commercial launch.

Nuvation Bio Inc. announced the U.S. Food and Drug Administration (FDA) approval of IBTROZI (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer, supported by strong clinical trial data and a robust financial outlook.

Nuvation Bio Inc. announced the successful election of directors, ratification of KPMG LLP as its independent auditor, and advisory approval of executive compensation at its 2025 Annual Meeting of Stockholders.

Nuvation Bio announces its Q1 2025 financial results, highlighting progress with taletrectinib, including an upcoming FDA decision and a strong cash position.

Nuvation Bio Inc. has entered into a commercial supply agreement with Asymchem Life Science (Tianjin) Co., Ltd. for the supply of taletrectinib drug product.

Nuvation Bio reports positive financial results for Q4 and full year 2024, highlighted by FDA Priority Review for taletrectinib and securing up to $250 million in non-dilutive financing.

Nuvation Bio has entered into a commercial supply agreement with Asymchem Laboratories for the supply of taletrectinib drug substance, ensuring a non-exclusive supply chain for its key product.

Nuvation Bio has entered into a $100 million loan agreement and a $150 million revenue interest financing agreement to support the development and commercialization of taletrectinib.

Nuvation Bio Inc. reports the departure of Dr. Jerry Wang, CEO of AnHeart Therapeutics, after achieving significant milestones, including regulatory approvals and successful integration post-merger.

Nuvation Bio submitted a New Drug Application for taletrectinib to the FDA and reported its third quarter 2024 financial results, highlighting a strong cash position and pipeline progress.

Nuvation Bio has appointed Philippe Sauvage as its new Chief Financial Officer, effective October 7, 2024.

Nuvation Bio's 2024 Annual Meeting saw the election of directors, ratification of auditors, approval of executive compensation, conversion of preferred stock, and board leadership changes.

Nuvation Bio reported its second quarter 2024 financial results, highlighted by a significant increase in R&D expenses due to the AnHeart Therapeutics acquisition, and provided updates on its clinical programs, including taletrectinib's progress towards a potential NDA filing.

Nuvation Bio finalizes its acquisition of AnHeart Therapeutics, incorporating key oncology assets and expanding its global reach.

Nuvation Bio announced its first quarter 2024 financial results, highlighted by the acquisition of AnHeart Therapeutics and progress in clinical trials.

Nuvation Bio finalized its acquisition of AnHeart Therapeutics on April 9, 2024, issuing shares and warrants to AnHeart securityholders and appointing two new directors to its board.

Nuvation Bio will acquire AnHeart Therapeutics in an all-stock transaction, transforming Nuvation Bio into a late-stage global oncology company with multiple clinical programs.

Nuvation Bio reported its Q4 and full year 2023 financial results, highlighted by the completion of a Phase 1 monotherapy study for NUV-868 and FDA clearance for NUV-1511.